<?xml version='1.0' encoding='utf-8'?>
<document id="31911485"><sentence text="Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors."><entity charOffset="59-73" id="DDI-PubMed.31911485.s1.e0" text="[14C]Alisertib" /><entity charOffset="75-82" id="DDI-PubMed.31911485.s1.e1" text="MLN8237" /><pair ddi="false" e1="DDI-PubMed.31911485.s1.e0" e2="DDI-PubMed.31911485.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31911485.s1.e0" e2="DDI-PubMed.31911485.s1.e1" /></sentence><sentence text="Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies"><entity charOffset="0-9" id="DDI-PubMed.31911485.s2.e0" text="Alisertib" /><entity charOffset="11-18" id="DDI-PubMed.31911485.s2.e1" text="MLN8237" /><pair ddi="false" e1="DDI-PubMed.31911485.s2.e0" e2="DDI-PubMed.31911485.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31911485.s2.e0" e2="DDI-PubMed.31911485.s2.e1" /></sentence><sentence text=" This metabolic profiling analysis was conducted as part of a broader phase 1 study evaluating mass balance, pharmacokinetics, metabolism, and routes of excretion of alisertib following a single 35-mg dose of [14C]alisertib oral solution (∼80 μCi) in three patients with advanced malignancies"><entity charOffset="209-223" id="DDI-PubMed.31911485.s3.e0" text="[14C]alisertib" /></sentence><sentence text=" On average, 87" /><sentence text="8% and 2" /><sentence text="7% of the administered dose was recovered in feces and urine, respectively, for a total recovery of 90" /><sentence text="5% by 14 days postdose" /><sentence text=" Unchanged [14C]alisertib was the predominant drug-related component in plasma, followed by O-desmethyl alisertib (M2), and alisertib acyl glucuronide (M1), which were present at 47"><entity charOffset="11-25" id="DDI-PubMed.31911485.s8.e0" text="[14C]alisertib" /><entity charOffset="92-113" id="DDI-PubMed.31911485.s8.e1" text="O-desmethyl alisertib" /><entity charOffset="124-150" id="DDI-PubMed.31911485.s8.e2" text="alisertib acyl glucuronide" /><pair ddi="false" e1="DDI-PubMed.31911485.s8.e0" e2="DDI-PubMed.31911485.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31911485.s8.e0" e2="DDI-PubMed.31911485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31911485.s8.e0" e2="DDI-PubMed.31911485.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31911485.s8.e1" e2="DDI-PubMed.31911485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31911485.s8.e1" e2="DDI-PubMed.31911485.s8.e2" /></sentence><sentence text="8%, 34" /><sentence text="6%, and 12" /><sentence text="0% of total plasma radioactivity" /><sentence text=" In urine, of the 2" /><sentence text="7% of the dose excreted, unchanged [14C]alisertib was a negligible component (trace), with M1 (0" /><sentence text="84% of dose) and glucuronide conjugate of hydroxy alisertib (M9; 0"><entity charOffset="17-28" id="DDI-PubMed.31911485.s14.e0" text="glucuronide" /><entity charOffset="42-59" id="DDI-PubMed.31911485.s14.e1" text="hydroxy alisertib" /><pair ddi="false" e1="DDI-PubMed.31911485.s14.e0" e2="DDI-PubMed.31911485.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31911485.s14.e0" e2="DDI-PubMed.31911485.s14.e1" /></sentence><sentence text="66% of dose) representing the primary drug-related components in urine" /><sentence text=" Hydroxy alisertib (M3; 20"><entity charOffset="1-18" id="DDI-PubMed.31911485.s16.e0" text="Hydroxy alisertib" /></sentence><sentence text="8% of the dose administered) and unchanged [14C]alisertib (26"><entity charOffset="43-57" id="DDI-PubMed.31911485.s17.e0" text="[14C]alisertib" /></sentence><sentence text="3% of the dose administered) were the major drug-related components in feces" /><sentence text=" In vitro, oxidative metabolism of alisertib was primarily mediated by CYP3A" /><sentence text=" The acyl glucuronidation of alisertib was primarily mediated by uridine 5'-diphospho-glucuronosyltransferase 1A1, 1A3, and 1A8 and was stable in 0"><entity charOffset="5-9" id="DDI-PubMed.31911485.s20.e0" text="acyl" /></sentence><sentence text="1 M phosphate buffer and in plasma and urine" /><sentence text=" Further in vitro evaluation of alisertib and its metabolites M1 and M2 for cytochrome P450-based drug-drug interaction (DDI) showed minimal potential for perpetrating DDI with coadministered drugs" /><sentence text=" Overall, renal elimination played an insignificant role in the disposition of alisertib, and metabolites resulting from phase 1 oxidative pathways contributed to &gt;58% of the alisertib dose recovered in urine and feces over 192 hours postdose" /><sentence text=" SIGNIFICANCE STATEMENT: This study describes the primary clearance pathways of alisertib and illustrates the value of timely conduct of human absorption, distribution, metabolism, and excretion studies in providing guidance to the clinical pharmacology development program for oncology drugs, for which a careful understanding of sources of exposure variability is crucial to inform risk management for drug-drug interactions given the generally limited therapeutic window for anticancer drugs and polypharmacy that is common in cancer patients" /><sentence text="" /></document>